21 results about "Human pancreas" patented technology

The invention relates to the technical field of biological medicine, and discloses an aromatic polyketone compound as well as a preparation method and application thereof. According to the aromatic polyketone compound, a compound I and a compound II are separated from an ethyl acetate extract of rice fermentation liquor of Crystalomyces hyricus, and the compound I and the compound II are respectively named as Crystaloketide A and Crystalomycin D. In-vitro anti-cancer activity tests are carried out on the Crystaloketide A and the Crystalomycin D. According to the aromatic polyketone compound disclosed by the invention, the anti-cancer activity of the Crystaloketide A and the Crystalomycin D. Results show that the compound I and the compound II have the effects of inhibiting human cervical cancer cells, human liver cancer cells, human nerve cancer cells and human pancreatic cancer cells respectively, so that the compound I and the compound II can be further prompted to be used for preparing anti-cancer drugs.

The invention relates to the field of biology, and provides a human immortalized pancreatic cancer fibroblast as well as a preparation method and application thereof.The human immortalized pancreatic cancer fibroblast comprises three cell strains which are all primary fibroblast cells extracted from tumor tissues of pancreatic ductal adenocarcinoma patients, the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are classified and named as the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 respectively, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are all Cell STR identification and immunofluorescence detection prove that the cell strain is a fibroblast cell strain. After the tumor-associated fibroblast and pancreatic cancer cells are co-cultured, the proliferation ability of the tumor cells is obviously enhanced, and the sensitivity of the tumor cells to a chemotherapeutic drug gemcitabine is reduced. A new thought is provided for diagnosis and treatment of pancreatic cancer, and based on the pancreatic cancer in-vitro co-culture model established in vitro, the application has important significance for researching the effect and related mechanisms of fibroblasts in the pancreatic cancer tumor microenvironment.

This invention relates to the regulation of pancreatic islet cell differentiation by regulatory factors related to N6-adenosine methylation modification of mRNA. Specifically, it relates to the use of (a) the ALKBH5 gene, or its protein, or its promoter; and / or (b) the YTHDF2 gene, or its protein, or its inhibitor, for the preparation of compositions or formulations for (1) promoting the differentiation of endodermal cells into pancreatic islet precursor cells and / or islet organoids; and / or (2) preventing and / or treating diabetes. The ALKBH5 of this invention regulates the N6-adenosine methylation modification of mRNA by... 6 Modification A controls the in vitro differentiation process of human pancreatic cells. Furthermore, the method of this invention holds promise as an effective method for in vitro culture of pancreatic islet cells, and could subsequently be applied to the treatment of diabetes.

NEO-201 is a humanized IgG1 monoclonal antibody (mAb) that is highly reactive against the majority of tumor tissues from a number of different cancer tumors, including colon, pancreatic, gastric, lung, breast and uterine cancers, but the majority of normal tissues are not recognized by such antibodies. Functional assays reveal that NEO-201 is capable of mediating both antibody dependent cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) against tumor cells. Furthermore, the growth of human pancreatic xenograft tumors in vivo is greatly weakened by using NEO-201 alone and in combination with human peripheral blood mononuclear cells (PBMCs) that are effector cell sources for ADCC. In-vivo biological distribution research in mice carrying human tumor xenografts reveals that NEO-201 is preferentially accumulated in tumors rather than organ tissues. Single dose toxicity studies in non-human primates demonstrate the safety and tolerance of NEO-201 because the transient reduction of circulating neutrophils is the sole associated side effect observed.

The application belongs to the field of medicine, and discloses a compound with the structure of formula I, a preparation method of the compound, and the compound is a pyrazole acylhydrazine derivative containing a diphenyl ether unit, which is obtained by substituting p-chloronitrobenzene with phenol, and then by reduction, diazotization, re-reduction, hydrochloric acid removal and hydrazide reaction; the pyrazole acylhydrazine derivative containing the diphenyl ether unit has obvious inhibitory effect on human pancreatic cancer cells, human breast cancer cells and human gastric cancer cells, and can be used as a potential new type of antitumor candidate drug molecule.

This invention relates to the field of biomedical technology, and discloses an aromatic polyketide compound, its preparation method, and its applications. The aromatic polyketide compound is derived from... Crystallomyces hypericus Compound I and Compound II were isolated from the ethyl acetate extract of rice fermentation broth and identified as Crystalloketide A and Crystallomycin D, respectively. In vitro anticancer activity tests were conducted on Crystalloketide A and Crystallomycin D. The results showed that Compound I and Compound II inhibited human cervical cancer cells, human liver cancer cells, human neurocancer cells, and human pancreatic cancer cells, respectively. Therefore, it is further suggested that Compound I and Compound II described in this invention can be used to prepare anticancer drugs.

The invention belongs to the technical field of biological medicine, and particularly discloses a tetravalent platinum rhein conjugate and application of the tetravalent platinum rhein conjugate in preparation of anti-cancer drugs, and the tetravalent platinum rhein conjugate has a structure as shown in a formula I or a formula II. Pharmacodynamic experiments show that compared with existing platinum drugs, rheinic acid, combined drugs of the platinum drugs and the rheinic acid and structural analogues, the tetravalent platinum rheinic acid conjugate disclosed by the invention shows unexpected ultra-strong inhibitory activity in order of magnitude on various solid tumor cells, especially on human pancreatic cancer cells MIAPaca-2. Animal in-vivo experiments further prove that the compound has an excellent tumor inhibition effect and good safety. The invention provides a candidate compound with great potential for developing a new generation of high-efficiency and low-toxicity anti-cancer drug, especially an anti-pancreatic cancer drug.

This invention discloses an acidic polysaccharide from Gynostemma pentaphyllum, AGPA12, its purification and extraction method, and its application in the preparation of anti-pancreatic cancer drugs. AGPA12 is mainly composed of mannose, glucuronic acid, rhamnose, glucose, galactose, and fucose, with a molar ratio of 1.05:1.74:6.29:1.40:69.48:19.03. The polysaccharide was extracted using an α-amylase-assisted water extraction and alcohol precipitation method, and purified by DEAE-Sepharose FF ion exchange chromatography and Sepharose CL6B gel chromatography. In vitro experiments showed that AGPA12 had significant inhibitory effects on the proliferation and migration of human pancreatic cancer AsPC1 cells, and its mechanism was related to the regulation of the MAPK signaling pathway and the expression of apoptosis-related proteins. This invention provides a new approach for the development of Gynostemma pentaphyllum polysaccharides and their application in anti-pancreatic cancer drugs.

The application discloses an anti-tumor small-molecule compound targeting ST3GAL1 and application thereof, and the small-molecule compound is N'-[1-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-methoxybenzohydrazide, and the structure is shown in the following formula I: The application obtains an anti-tumor small-molecule compound targeting ST3GAL1 through virtual screening, the small-molecule compound can inhibit the expression of ST3GAL1, and has the potential to be applied to tumor treatment and preparation of anti-tumor drugs; experiments show that the small-molecule compound has significant inhibitory effects on human pancreatic cancer PANC-1 cell lines and human in situ pancreatic cancer BxPC-3 cell lines after 48 hours of action, and the inhibitory effects are in a dose-dependent manner, wherein the IC50 value of the small-molecule compound on the PANC-1 cells is 42.17 micromoles, and the IC50 value of the small-molecule compound on the BxPC-3 cells is 46.83 micromoles.

The invention discloses an oleanolic acid acylhydrazone derivative as well as a preparation method and application thereof. The oleanolic acid acylhydrazone derivatives have a structural formula shown in the following formula I. In the structural formula, R is selected from halogen-substituted pyridine and hydroxyl-substituted naphthyl. The invention provides a series of oleanolic acid acylhydrazone derivatives with novel structures, and the oleanolic acid acylhydrazone derivatives have relatively good inhibition effects on human breast cancer cells MDA-MB-231 and human pancreatic cancer cells Mia paca-2, and can be used for preparing an anti-cancer drug. The compound can be used for preparing anti-tumor drugs.

The invention discloses a tetra-heterocyclic compound as well as a preparation method and application thereof. The invention provides a compound as shown in a formula I, and a stereoisomer or pharmaceutically acceptable salt thereof. The compound disclosed by the invention has good proliferation inhibition activity on one or more cancer cells of human non-small cell lung cancer cells NCI-H358 (KRAS G12C mutation) containing KRAS mutation, human metastatic pancreatic adenocarcinoma cells AsPC-1 (KRAS G12D mutation) and human pancreatic cancer cells Capan-1 (KRAS G12V mutation). Formula I.

The application discloses a 1,3,4-oxadiazole derivative containing a biphenyl unit and a preparation method and application thereof, a structural formula of the derivative is shown as formula I, and the preparation method is that an oxadiazole molecule containing a phenoxy (sulfone) methyl is subjected to a substitution reaction with 2-bromo-4'-phenyl phenylethanone in a solvent containing potassium carbonate to obtain a target compound. The 1,3,4-oxadiazole derivative containing the biphenyl unit has obvious inhibiting effects on human pancreatic cancer cells (PANC-1) and human hepatoma cells (HepG2), and can be used as a potential new type of antitumor candidate drug molecule.

A drug for treating pancreatic cancer and use thereof. Cell experiments demonstrate that the pharmaceutical composition has a synergistic effect of inhibiting the survival of human pancreatic cancer cells and inducing the periodic inhibition and apoptosis of human pancreatic cancer cells. Moreover, anti-tumor efficacy experiments on a CDX model and clinical trials demonstrate that, compared with the prior art, the pharmaceutical combination achieves an unexpected therapeutic effect and exhibits a synergistic effect of inhibiting tumor growth. The present invention provides a better option for the treatment of pancreatic cancer.

This application relates to the pharmaceutical field, and particularly to SOS1 protein degraders and their applications. The compounds of this application can effectively inhibit tumor cell proliferation and degrade SOS1 protein in tumor cells, with a maximum degradation rate of 96.15%. Compared with existing small molecule compounds, the compounds of this application exhibit a more sustained inhibitory effect on SOS1 signaling and a more significant inhibitory effect on the growth of human MIA PaCa-2 pancreatic cancer subcutaneous xenografts in mice, with a maximum tumor volume inhibition rate (TGI) of 81.3%.

This invention relates to a novel *Bletilla striata* alkaloid boric acid compound, its preparation method, and its use in the preparation of antitumor drugs. The general chemical formula of this class of compounds is shown in structural formulas (I) and (II). In vitro antitumor activity screening results showed that compounds of formulas I and II possess broad-spectrum antitumor activity, exhibiting strong inhibitory activity against human liver cancer (HepG2), human pancreatic cancer (SW1990), human ovarian cancer (A2780), human breast cancer (MCF7), and human colon cancer (SW480) cell lines. Compounds N-3 and N-4 showed strong inhibitory effects against all five tested tumor cell lines, with IC50 values ​​exceeding 100%. 50 The values ​​were 0.26–0.89 μM and 0.22–0.91 μM, respectively; compounds N-1, N-3, and N-4 exhibited strong inhibitory effects on the human pancreatic cancer (SW1990) cell line, with IC50 values ​​of 0.26–0.89 μM and 0.22–0.91 μM, respectively. 50 The concentrations were 0.97, 0.45, and 0.63 μM, respectively, significantly superior to the control drug topotecan; simultaneously, compounds N-3 and N-4 also exhibited strong inhibitory effects on the human breast cancer (MCF7) cell line, with IC50 values ​​of 0.97, 0.45, and 0.63 μM. 50 The concentrations were 0.80 and 0.65 μM, respectively, significantly better than the control drug topotecan. Therefore, the new cypermethrin borate compound holds promise for development into a novel antitumor drug.

An abnormal expression of cytoplasmic Cep63 has been found to be enhanced in tumor cells of which the formation has been promoted due to p62 deficiency. Similarly, the expression of cytoplasmic Cep63 has been found to be enhanced in human pancreatic cancer. On the other hand, suppressing the expression of cytoplasmic Cep63 in the tumor cells and the human pancreatic cancer has been found to inhibit the proliferation thereof. Thus, a new target molecule contributing to p62-related tumor formation has been found, and cancer can be treated or prevented by suppressing the function of the molecule. Cancer can also be detected using the expression of the target molecule as an indicator.

The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and / or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.

Provided herein are materials and methods relating to the fields of immunology and diabetes. More specifically, provided herein are methods and compositions directed to humanized antibodies to human zinc transporter-8 (ZnT8), a biomarker of human pancreatic beta-cells.

The invention discloses a human pancreatic cancer cell line PDAC-X6 and application thereof, and belongs to the field of microbial animal cell lines. The human pancreatic cancer cell line is named as a human pancreatic cancer cell line PDAC-X6 homo sapiens, and is preserved in the China Center for Type Culture Collection on November 22, 2025, and the preservation number is CCTCC NO: C2025355. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a cell model for occurrence, development or metastasis of pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to cell models for studying the differentiation mechanism, cell morphology and dysfunction and tumor infiltration and metastasis mechanism of pancreatic cancer and guiding clinical comprehensive diagnosis and treatment. The human pancreatic cancer cell line PDAC-X6 can be applied to research on the occurrence mechanism of pancreatic cancer and screening of drugs for preventing and treating pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a pancreatic cancer animal model.

The application discloses a novel coumarin derivative containing a quinazoline unit (as shown in structural formula I), and a preparation method thereof. The preparation method comprises the following steps: subjecting a coumarin molecule A treated by a sodium hydroxide solution to etherification reaction with a 4-chloroquinazoline molecule B in acetonitrile by heating, and then subjecting an intermediate product C obtained by the reaction to reaction with benzyl chloride or bromoethane in acetonitrile by heating, so as to obtain the novel coumarin derivative I containing the quinazoline unit. The novel coumarin derivative containing the quinazoline unit is a novel compound, has obvious inhibiting effect on human pancreatic cancer cells (PANC-1), human gastric cancer cells (SGC7901) and human breast cancer cells (MDA-MB-231), and can be developed as a novel anti-tumor drug candidate molecule.

The invention relates to the technical field of biopharmacy, in particular to application of recombinant protein DEL-1 in preparation of a medicine for improving a human islet insulin secretion function. The invention discovers that the recombinant protein DEL-1 has a remarkable improvement effect on insulin secretion dysfunction in various human islet injury models. Experiments show that in a high glucose combined palmitic acid damage model and an inflammatory cytokine damage model, the DEL-1 can significantly improve the insulin secretion function of the human pancreas islet. Specifically, compared with an injured group, after DEL-1 treatment, the glucose stimulation index of the human pancreas islet and the relative secretion amount of insulin under high glucose stimulation are remarkably increased, and it is proved that DEL-1 has the definite effect of promoting the insulin secretion function of the human pancreas islet beta cells.